Fundamental results of the clinical trial of chronic atopic dermatitis

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Credit: public domain CC0

The results of a clinical trial conducted by researchers at Trinity College Dublin on the treatment of atopic dermatitis have been published today. The Lancet magazine (Friday, May 21, 2021). The results of the clinical trial at the School of Medicine, Trinity College and St James’s Hospital in Dublin have shown that the drug upadacitinib is the most effective treatment to date for this chronic and recurrent inflammatory disease. Research is vital, as there is an unmet need for therapies that provide remission of symptoms in moderate to severe atopic dermatitis.

The publication reports the efficacy and safety results of upadacitinib compared with placebo for the treatment of moderate to severe atopic dermatitis in adults and adolescents. This fundamental Phase 3 global study included 1,600 patients and was conducted over the past two years at the Wellcome Trust / Health Research Board’s clinical research facility at St James’s Hospital.

Atopic dermatitis is a chronic, recurrent inflammatory disease characterized by a cycle of itching and intense scratches that lead to cracked, scaly, breathing skin. It affects up to 10% of adults and 25% of children. Between 20 and 46 percent of adults with atopic dermatitis have moderate to severe illness. The range of symptoms is a significant physical, psychological and economic burden for people affected by the disease.

The results show that upadacitinib is so far the maximum for atopic dermatitis a . The magnitude and breadth of the effect of placebo treatment on multifaceted aspects of atopic dermatitis provides evidence that targeted therapy that blocks multiple inflammatory pathways could help address substantial unmet needs in the treatment of moderate to severe atopic dermatitis. severe.

These fundamental findings could transform treatment goals and standards of care for moderate to severe patients. .

Professor Alan Irvine, Faculty of Medicine, Trinity College and principal investigator, said:

“Atopic dermatitis is an common skin inflammatory disease that, when severe, has a very significant impact on quality of life. These results are hugely encouraging and we hope they offer an additional treatment option for patients soon. The success of this clinical trial also shows the value of investing in our Trinity research facilities at St James’s Hospital, which means that Irish patients have access to advanced therapies and that Irish doctors and nurses they acquire valuable research skills. ”

Baricitinib shows long-term efficacy for atopic dermatitis

More information:
Emma Guttman-Yassky et al, upadacitinib once daily versus placebo in adolescents and adults with moderate to severe atopic dermatitis (Measure 1 and Measure 2): results of two randomized, double-blind, duplicate, controlled phase 3 trials. The Lancet (2021). DOI: 10.1016 / S0140-6736 (21) 00588-2

Citation: Fundamental results of the clinical trial on the chronic condition of atopic dermatitis (2021, May 21) retrieved May 22, 2021 at trial-chronic.html

This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link



Recent Posts

Cisco Duo wins Best in KLAS again for the second year in a row
Co-author of Allison Norfleet The results of the Best in KLAS Awards 2024: Software and Services the...
Read More
Enhance your Cisco HIMSS24 experience
The Cisco Customer Experience Healthcare Practice helps customers leverage the use of Cisco technology...
Read More
HIMSS 2024 Find out before you go
The future of healthcare is coming into focus! Now more than ever, we believe that technology is a critical...
Read More

Related Posts